An APP gene test checks for disease-causing changes in the amyloid precursor protein gene when dementia symptoms worsen and early-onset Alzheimer disease is possible. Clinical testing uses full-gene sequencing to find those variants, while counseling before and after helps families act on the result. Pathogenic variants in APP cause early-onset Alzheimer disease beginning before age 65 and account for less than 10% of all early-onset cases, according to the MedlinePlus Genetics page on APP. Indiana University lists Alzheimer dementia as starting with subtle memory failure that slowly becomes severe and incapacitating, which is why progression often prompts questions about inherited causes, as described on the Indiana University testing laboratory page for APP sequencing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the APP test look for?
- How accurate is it when symptoms progress?
- How should families prepare?
- What are the next steps after results?
What does the APP test look for?
APP gives instructions for making amyloid precursor protein. A harmful change can lead to dominantly inherited early-onset Alzheimer disease.
APP is tested alongside PSEN1 and PSEN2 because all three genes can carry such inherited changes. The clinical test sequences the full APP gene to detect disease-causing variants. A doctor usually considers it when onset is early, symptoms progress from mild forgetfulness toward severe impairment, and family history suggests dominant inheritance across generations.
How accurate is it when symptoms progress?
For the APP variant itself, sequencing is a direct search for a known kind of disease-causing change. For predicting common sporadic Alzheimer disease, however, genetic testing is limited. No reliable genetic test exists for common sporadic Alzheimer disease, so testing can at best show susceptibility and can never predict with certainty who will or will not develop it, according to the Alzheimer Society of Canada guide to genetic testing.
The picture differs for dominantly inherited early-onset disease. APP, PSEN1 and PSEN2 mutations confer almost 100% risk, usually with onset before age 60, so an identified carrier will almost certainly develop disease, according to the ACMG and NSGC joint practice guidelines. That contrast matters: a positive result in a true familial pattern carries strong weight, while a negative or unclear result does not rule out sporadic disease.
How should families prepare?
Preparation starts with a careful family history. Note ages at first symptoms, pace of decline, diagnoses, autopsy findings if available, and cases on both sides of the family.
Then meet with a clinician or certified genetic counselor before testing. Preparation requires pre- and post-test counseling to review family history, test relevance, process, risks, benefits, and meaning of positive or negative results, according to the Alzheimer Society of Canada guide linked above. Families can use this time to: The Alzheimer's Association also advises talking with a genetic counselor before deciding on Alzheimer genetic testing and again after receiving results, using its counselor directory to find local help, as explained on the Alzheimer's Association blog on genetic testing.
- Clarify whether testing the person with symptoms or another relative gives the clearest answer
- Discuss employment, insurance, privacy, and emotional effects
- Plan how results will be shared with siblings and adult children
- Ask what follow-up care, monitoring, or research options exist locally
What are the next steps after results?
A positive result for a harmful APP variant points to a dominantly inherited cause. Children of a parent carrying a faulty APP, PSEN1 or PSEN2 gene have a 50% chance of inheriting it, while people who do not inherit it cannot pass it to their own children, according to the Alzheimer Society of Canada guide linked above. Adult children may then consider their own counseling, predictive testing choices, care planning, and family communication. A negative result needs careful interpretation.
It can be reassuring in a family with a known APP variant when the person did not inherit that specific change. Without a known family variant, it does not remove the risk of sporadic Alzheimer disease or explain progressing symptoms by itself. When the affected relative has died, records can still guide decisions. Clinicians can propose retrospective diagnosis by reviewing autopsy reports and medical records before deciding about family testing. Bring death certificates, neurology notes, imaging reports, medication lists, and any prior genetic reports to that review.
